The stock of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is a huge mover today! The stock increased 4.06% or $0.55 on November 23, hitting $14.1. About 682,883 shares traded hands or 12.38% up from the average. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 43.58% since April 22, 2016 and is uptrending. It has outperformed by 38.18% the S&P500.
The move comes after 9 months positive chart setup for the $934.18 million company. It was reported on Nov, 24 by Barchart.com. We have $14.66 PT which if reached, will make NASDAQ:MNTA worth $37.37 million more.
Analysts await Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report earnings on February, 16. They expect $-0.21 earnings per share, up 51.16% or $0.22 from last year’s $-0.43 per share. After $-0.26 actual earnings per share reported by Momenta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Ratings Coverage
Out of 9 analysts covering Momenta Pharmaceuticals (NASDAQ:MNTA), 5 rate it a “Buy”, 2 “Sell”, while 2 “Hold”. This means 56% are positive. $31 is the highest target while $6 is the lowest. The $17.11 average target is 21.35% above today’s ($14.1) stock price. Momenta Pharmaceuticals has been the topic of 17 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Leerink Swann on Tuesday, October 13 with “Outperform”. The rating was upgraded by Maxim Group on Friday, January 8 to “Hold”. The firm has “Neutral” rating by Goldman Sachs given on Thursday, August 6. The rating was initiated by Goldman Sachs on Monday, June 6 with “Neutral”. The company was upgraded on Tuesday, October 11 by Barclays Capital. On Wednesday, September 7 the stock rating was downgraded by Maxim Group to “Sell”. Aegis Capital initiated the stock with “Hold” rating in Tuesday, November 22 report. Leerink Swann maintained Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rating on Wednesday, May 4. Leerink Swann has “Outperform” rating and $18 price target. The firm has “Overweight” rating given on Friday, November 13 by JP Morgan. The company was initiated on Monday, November 23 by Barclays Capital.
According to Zacks Investment Research, “Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.”
Insitutional Activity: The institutional sentiment decreased to 1.35 in 2016 Q2. Its down 0.03, from 1.38 in 2016Q1. The ratio is negative, as 23 funds sold all Momenta Pharmaceuticals, Inc. shares owned while 30 reduced positions. 15 funds bought stakes while 58 increased positions. They now own 57.30 million shares or 1.40% less from 58.11 million shares in 2016Q1.
Geode Cap Ltd Liability has invested 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). The Rhode Island-based Amica Retiree Med Tru has invested 0.1% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). New York State Common Retirement Fund holds 0% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) for 256,437 shares. Quantitative Systematic Strategies Limited Company has 15,394 shares for 0.08% of their US portfolio. National Bank Of America Corp De owns 798,795 shares or 0% of their US portfolio. Tower Capital Ltd Liability Com (Trc) last reported 600 shares in the company. D E Shaw & Comm last reported 1.75 million shares in the company. Manufacturers Life Insurance The holds 0% or 44,823 shares in its portfolio. Vanguard Gp Inc holds 4.75M shares or 0% of its portfolio. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Finemark Bancorp & last reported 1,223 shares in the company. Bogle Mgmt L P De has invested 0.01% of its portfolio in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Citigroup has 0% invested in the company for 10,041 shares. Blackrock Advsr Ltd Liability Corporation, a Delaware-based fund reported 90,261 shares. Macquarie Gru accumulated 80,000 shares or 0% of the stock.
Insider Transactions: Since June 1, 2016, the stock had 0 insider purchases, and 11 insider sales for $325,231 net activity. $13,276 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Shea Richard P. Shares for $14,911 were sold by Roach James M.. 5,880 shares were sold by WHEELER CRAIG A, worth $70,704 on Friday, August 19. $12,644 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Kaundinya Ganesh Venkataraman on Friday, August 19. $67,600 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) was sold by Shapiro Bennett M on Wednesday, June 1. The insider Leicher Bruce sold $14,069.
More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Fool.com which released: “Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales” on November 04, 2016, also Fool.com with their article: “Why Momenta Pharmaceuticals, Inc. Jumped Higher Today” published on October 11, 2016, Fool.com published: “Why Momenta Pharmaceuticals, Inc. Was Up Today” on January 08, 2016. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Fool.com and their article: “Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February — Here’s Why” published on March 04, 2016 as well as Fool.com‘s news article titled: “Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?” with publication date: August 09, 2016.
MNTA Company Profile
Momenta Pharmaceuticals, Inc., incorporated on May 17, 2001, is a biotechnology company. The Firm is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Firm focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. The Firm has developed generic version of Lovenox (enoxaparin sodium injection).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.